论文部分内容阅读
目的:比较美罗培南与亚胺培南-西司他丁钠对急性白血病患者伴肺部感染的临床疗效。方法:选取2015年10月—2016年10月期间收治的急性白血病患者伴肺部感染70例临床资料,将其随机分为观察组和对照组(每组35例);观察组患者给予美罗培南治疗,对照组患者给予亚胺培南-西司他丁钠治疗,比较两组患者用药后的总有效率和不良反应的发生率。结果:观察组患者治疗后的总有效率为94.29%明显高于对照组为77.14%(P<0.05),细菌清除率为42.86%高于对照组为20.00%(P<0.05),不良反应的发生率明显低于对照组(P<0.05)。结论:美罗培南用于治疗急性白血病患者伴肺部感染,抗肺部感染的临床疗效优于亚胺培南-西司他丁钠,且细菌清除率较高,不良反应的发生率较低。
AIM: To compare the clinical efficacy of meropenem and imipenem-cilastatin sodium in patients with acute leukemia with pulmonary infection. Methods: The clinical data of 70 patients with acute leukemia and pulmonary infection admitted from October 2015 to October 2016 were selected and randomly divided into observation group and control group (35 cases in each group). The patients in observation group were given Meropenem The patients in the control group were treated with imipenem-cilastatin sodium. The total effective rate and incidence of adverse reactions after treatment were compared between the two groups. Results: The total effective rate of the observation group after treatment was 94.29%, which was significantly higher than that of the control group (77.14%, P <0.05). The bacterial clearance rate was 42.86% higher than that of the control group (20.00%, P <0.05) The incidence was significantly lower than that of the control group (P <0.05). Conclusion: Meropenem is superior to imipenem-cilastatin sodium in the treatment of acute leukemia patients with pulmonary infection and anti-pulmonary infection, and the bacterial clearance rate is higher and the incidence of adverse reactions is lower.